FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to experimental pharmacology, and can be used to correct the aggregation ability of platelets. A method for reducing the aggregation capacity of platelets includes the induction of platelet aggregation using adenosine diphosphate. Blood incubation is carried out with a peptide with the amino acid sequence UEHLERALNSS or with a peptide with the amino acid sequence UEQLERALNTS at a final concentration of 30 mcg/ml.
EFFECT: reduction of platelet aggregation ability.
1 cl, 1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR INCREASING THE SURVIVAL OF HUMAN ENDOTHELIAL CELLS | 2021 |
|
RU2751332C1 |
METHOD OF CORRECTION OF STRUCTURAL DAMAGES IN PLACENTA WITH PEPTIDE IMITATING ALPHA-HELIX B ERYTHROPOIETIN IN ADMA-LIKE MODEL OF PREECLAMPSIA | 2020 |
|
RU2724402C1 |
RGD-LIKE PEPTIDES | 2009 |
|
RU2396271C1 |
METHOD FOR CORRECTING MICROCIRCULATION DISORDERS IN KIDNEY WITH PEPTIDE THAT MIMICS ALPHA-HELIX B OF ERYTHROPOIETIN IN ISCHEMIA-REPERFUSION INJURY | 2021 |
|
RU2751413C1 |
THROMBOCYTE AGGREGATION-INHIBITING HETEROMERIC PEPTIDES BASED ON IMIDAZO[4,5-e]BENZO[1,2-c;3,4-c']DIFUROXANE | 2014 |
|
RU2550223C1 |
METHOD OF DETERMINING ANTI-THROMBOTIC EFFECT OF ACETYLSALICYLIC ACID | 2007 |
|
RU2379684C2 |
METHOD FOR CORRECTING MICROCIRCULATORY DISORDERS OF THE RETINA WITH ASIALATED ERYTHROPOIETIN | 2021 |
|
RU2762892C1 |
METHOD OF ASSESSING THE EFFICIENCY OF ANTI-CLEGGANT MEDICINAL PRODUCT IN WHOLE PERIPHERAL BLOOD SAMPLES | 2022 |
|
RU2800671C1 |
METHOD FOR CORRECTION OF MICROCIRCULATORY DISORDERS OF THE RETINA WITH LOW-SIALATED ERYTHROPOIETIN | 2021 |
|
RU2750966C1 |
METHOD OF PLACENTAL MICROCIRCULATION CORRECTION BY PEPTIDE IMITATING B ERYTHROPOIETIN ALPHA-SPIRAL WITH ADMA-LIKE PRE-ECLAMPSIA MODEL | 2020 |
|
RU2731919C1 |
Authors
Dates
2021-07-21—Published
2021-02-17—Filed